CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised

- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain Manhattan, Live
- Canine parvovirus, strain Cornell 780916, Live
- Canine distemper virus, strain Lederle, Live

Product identification

Medicine name:
CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS
Canigen DHPPi Lyofilisaat en oplosmiddel voor suspensie voor injectie
Canigen DHPPi Lyophilisat et solvant pour suspension injectable
Canigen DHPPi Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension

Active substance:
Canine adenovirus 2, strain Manhattan, Live
Canine parainfluenza virus, strain Manhattan, Live
Canine parvovirus, strain Cornell 780916, Live
Canine distemper virus, strain Lederle, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Canine adenovirus 2, strain Manhattan, Live
4.00 log10 50% tissue culture infectious dose / 1.00 Dose

Canine parainfluenza virus, strain Manhattan, Live
5.00 log10 50% tissue culture infectious dose / 1.00 Dose

Canine parvovirus, strain Cornell 780916, Live
5.00 log10 50% tissue culture infectious dose / 1.00 Dose

Canine distemper virus, strain Lederle, Live
3.00 log10 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD04

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Belgium

Available in:
Belgium

Package description:
Cardboard box of 1 vial lyophilisate and 1 vial solvent
Plastic box of 100 vials lyophilisate and 100 vials solvent
Plastic box of 50 vials lyophilisate and 50 vials solvent
Plastic box of 25 vials lyophilisate and 25 vials solvent

Plastic box of 10 vials lyophilisate and 10 vials solvent
Plastic box of 5 vials lyophilisate and 5 vials solvent
Plastic box of 1 vial lyophilisate and 1 vial solvent
Cardboard box of 100 vials lyophilisate and 100 vials solvent
Cardboard box of 50 vials lyophilisate and 50 vials solvent
Cardboard box of 25 vials lyophilisate and 25 vials solvent
Cardboard boxof 10 vials lyophilisate and 10 vials solvent
Cardboard box of 5 vials lyophilisate and 5 vials solvent

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
6/10/2016

Manufacturing sites for batch release:
Virbac

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V501733

Date of authorisation status change:
6/10/2016

Reference member state:
France

Procedure number:

FR/V/0297/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.